



Europad
European Opiate Addiction Treatment Association



World Federation for the
Treatment of
Opioid Dependence

9th European Congress on

Heroin Addiction & Related Clinical Problems

European Opiate Addiction Treatment Association

**28-30 May
2010**

www.europad.org

Program

Westin Hotel
ZAGREB
Croatia

Europad

EUROPEAN OPIATE ADDICTION TREATMENT ASSOCIATION

EUROPAD formerly EUMA was founded in Geneva (Switzerland) on September 26, 1994. It shall remain independent of political parties and of any government.

The vision

EUROPAD exists to improve the lives of opiate misusers and their families and to reduce the impact of illicit drug use on society as a whole. The Association works to develop opiate addiction treatment in Europe but also aims to make a major contribution to the knowledge of, and attitudes to, addiction treatment worldwide

Board of Directors

Icro Maremmani	President	Pisa, Italy
Marc Reisinger	Vice-President	Bruxelles, Belgium
Andrej Kastelic	General Secretary	Ljubljana, Slovenia

Oleg Aizberg, Minsk, Belarus
Michael Arieli, Jerusalem, Israel
Marc Auriacombe, Bordeaux, France
Safet Blakaj, Pristina, Kosovo
Olof Blix, Jönköping, Sweden
Colin Brewer, London, UK
Pascal Courty, Clermont Ferrand, France
Jean Jacques Deglon, Geneve, Switzerland
Sergey Dvoriak, Kiev, Ukraine
Michael Farrell, London, UK
Gabriele Fischer, Vienna, Austria
Milazim Gjocjaj, Pristina, Kosovo
Haraldsen Martin, Sandefjord, Norway
Liljana Ignjatova, Skopje, Macedonia
Ante Ivancic, Porec, Croatia
Nikola Jelovac, Split, Croatia
Minja Jovanovic, Kragujevac, Serbia
Euangelos Kafetzopoulos, Athens, Greece
Alexander Kantchelov, Sofia, Bulgaria
Sergey Koren, Moscow, Russia
Alexander Kozlov, Moscow, Russia
Gunnar Kristiansen, Oslo, Norway
Mercedes Lovrecic, Ljubljana, Slovenia

Nermana Mehic-Basara, Sarajevo, Bosnia and Herzegovina
Haim Mell, Jerusalem, Israel
Vladimir Mendeleovich, Kazan, Russia
Genci Mucullari, Tirana, Albania
Lubomir Okruhlica, Bratislava, Slovak Republic
Matteo Pacini, Pisa, Italy
Pier Paolo Pani, Cagliari, Italy
Luis Patricio, Lisbon, Portugal
Tijana Pavicevic, Podgorica, Montenegro
Paul Quigley, Dublin, Ireland
Marina Roganovic, Kotor, Montenegro
Rainer Schmid, Vienna, Austria
Aneta Spasovska Trajanovska, Skopje, Macedonia
Karina Stainbarth-Chmielewska, Warsaw, Poland
Marlene Stenbacka, Stockholm, Sweden
Emilis Subata, Vilnius, Lithuania
Marta Torrens, Barcelona, Spain
Didier Touzeau, Paris, France
Albrecht Ulmer, Stuttgart, Germany
Peter Vossenbergh, Deventer, The Netherlands
Nikola Vuckovic, Novi Sad, Serbia
Helge Waal, Oslo, Norway
Stephan Walcher, Munich, Germany
Wojciech Rudalski, Warsaw, Poland

Under the Patronage of

**Republic of Croatia Ministry of Health and Social Welfare
World Federation for the Treatment of Opioid Dependence**

Vincent P. Dole Dual Diagnosis Unit, Santa Chiara University Hospital
Department of Psychiatry NPB, University of Pisa, Italy

PISA-SIA (Study and Intervention on Addiction) Group
G. De Lisio Institute of Behavioural Sciences, Pisa, Italy

Italian Journal of Addictions
Heroin Addiction and Related Clinical Problems



Promoted by

European Opiate Addiction Treatment Association - EUROPAD
Europad-Italia

Italian Society of Addiction Medicine - SITD
From Science to Public Policy Association - AU CNS

Venue:

Westin Hotel Zagreb

**Krsnjavoga 1
HR-10000, Zagreb, Croatia
01 48 92 000
www.westinzagreb.com**

Presidents

I. Maremmani (Pisa, Italy)
A. Ivancic (Porec, Croatia)

Scientific Committee

Coordinators

I. Maremmani (Pisa, Italy)
M. Reisinger (Bruxelles, Belgium)
A. Kastelic (Ljubljana, Slovenia)
A. Ivancic (Porec, Croatia)

Members

EUROPAD Board of Directors

Local Committee

Slavko Sakoman (Zagreb, Croatia)
Mirjana Orban (Zagreb, Croatia)
Ante Ivancic (Porec, Croatia)
Hrvoje Tiljak (Zagreb, Croatia)
Marina Kuzman (Zagreb, Croatia)
Zeljko Kljucovic (Split, Croatia)
Marija Kribl (Osijek, Croatia)
Karmen Juresko (Rijeka, Croatia)
Nikola Jelovac (Split, Croatia)

Organizing Committee

Ti.Gi. Congress

Via Udine, 12
58100 GROSSETO, Italy, EU
Phone: +39 0564412038- Fax: +39 0564412485
E-mail: info@tigicongress.com

AU-CNS

Via XX Settembre, 83
55045 PIETRASANTA, Italy, EU
Phone: +39 0584790073
Fax: +39 058472081
E-mail: info@aucns.org

Venue

The Westin Zagreb
Krsnjavoga 1 Zagreb, 10000 Croatia Map
Phone: (385)(1) 489 2000

Friday, May 28th, 2010

09:30 **Selected paper**

15:00 **Special Event - Book presentation**

17:00 *Opening Ceremony* (I. Maremmani, Pisa, Italy, EU and A. Ivancic, Porec, Croatia)

17:15 **Introduction** - M. Parrino (New York, USA)

17:45 **Introduction** - A. Kastelic (Ljubljana, Slovenia)

18:15 **Main Lecture** - R. Newman (New York, NY, USA)

19:00 **Main Lecture** - M. Krausz (Vancouver, BC, Canada)

20:30 *Welcome Cocktail and EUROPAD Chimera Award*

Saturday, May 29th, 2010

8:00 **SEEAnet Meeting**

9:00 **Main Lecture** - G. Gerra (Vienna, UNODC)

9:30 **Main Lecture** - L. Finnegan (Avalon, NJ, USA)

10:30 *Break*

11:00	Symposium I HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS	Symposium II GENDER DIFFERENCES IN HEROIN ADDICTS	Symposium III HEROIN ADDICTION AND PREGNANCY: THE MOTHER STUDY
	<i>Chairman: I. Maremmani (Pisa, Italy, EU)</i>	<i>Chairman: L. Ignjatova (Skopje, Republic of Macedonia)</i>	<i>Chairman: K. Kaltenbach (Philadelphia, PA, USA)</i>

13:00 *Break*

15:00	Symposium IV NATIONAL REGULATIONS AND GUIDELINES FOR THE TREATMENT OF OPIOID DEPENDENCE; NECESSITIES OR OBSTACLES	Symposium V HEROIN ADDICTION AND INFECTIOUS DISEASES	Symposium VI BUPRENORPHINE: PRACTICE AND PERSPECTIVE
	<i>Chairman: H. Waal (Oslo, Norway)</i>	<i>Chairman: L. Somaini (Biella, Italy, EU)</i>	<i>Chairman: D. Touzeau (Paris, France, EU)</i>

17:00 *Break*

17:30	Symposium VII PSYCHIATRIC COMORBIDITY OF HEROIN ADDICTS	Symposium VIII PSYCHOTHERAPIES FOR PATIENTS TREATED WITH OPIOID AGONISTS	Symposium IX OFFICE-BASED TREATMENT FOR OPIATE DEPENDENCE
	<i>Chairman: P.P. Pani (Cagliari, Italy, EU)</i>	<i>Chairman: A. Kantchelov (Sofia, Bulgaria, EU)</i>	<i>Chairman: A. Ivancic (Porec, Croatia)</i>

19:30 *End of Session*

Sunday, May 30th, 2010


8:30 **WFTOD Meeting**

9:30 **Main Lecture** - A. Dunlop (Newcastle, Australia)

10:30 *Break*

11:00	Symposium X OPIOID TREATMENT & ALCOHOL CONSUMPTION: MYTHS AND REALITY	Symposium XI MISUSE AND RISKS IN OPIOID TREATMENT	Symposium XII OPIOID TREATMENT IN EASTERN EUROPE AND FORMER SOVIET UNION
	<i>Chairman: L. Patricio (Lisbon, Portugal)</i>	<i>Chairman: R. Lubran (Rockville, MD, USA)</i>	<i>Chairman: V. Mendelevich (Kazan, Russia)</i>

13:00 **Closing Ceremony** - M. Reisinger (Bruxelles, Belgium) and **Welcome to the next European Europad Conference** -



Friday, May 28th, 2010

Plenary Room

SELECTED PAPER

Chairman: *I. Maremmani*

(Pisa, Italy, EU)

- 9:30 **Z. Alexandercikova** (*Bratislava, Slovak Republic*)
Improvement of Access to Treatment for People with Alcohol and Drug Related Problems – IATPAD Project
- 10:00 **C. Pieri** (*Bologna, Italy, EU*)
Anxious patient: medical care
- 10:30 **M. Toseva** (*Skopje, Republic of Macedonia*)
Drug use, sex work and gender implication
- 11:00 **N. Jelovac** (*Split, Croatia*)
Long-term follow-up of heroin addict – Natural history of heroin addiction in Croatia
- 11:30 **I.J. Marion** (*New York, NY, USA*)
Transforming substance abuse treatment in New York State
- 12:00 **C. Roncero Alonso** (*Barcelona, Spain, EU*)
The Proteus Study
- 12:30 **H. Stöver**
Opioid substitution treatment in Germany: insights and opportunities
- 13:00 **P. Vossenber** (*Deventer, The Netherlands*)
Minor side-effects during opiate maintenance, major nuisance for patient
- 13:30 **L. Okruhlica** (*Bratislava, Slovak Republic*)
Sexual functioning of the patients in methadone maintenance
- 14:00 **BREAK**

SPECIAL EVENT

- 15:00 **BOOK PRESENTATION: THE PRINCIPLES AND PRACTICE OF METHADONE TREATMENT (Icro Maremmani Editor)**
DISCUSSANT: M. Pacini (*Pisa, Italy, EU*)
- 16:30 **BREAK**
- 17:00 **OPENING CEREMONY: I. Maremmani** (*Pisa, Italy, EU*) and **A. Ivancic** (*Porec, Croatia*)
MAIN LECTURES - Chairmen: A. Ivancic (*Porec, Croatia*) - **N. Jelovac** (*Split, Croatia*)
- 17:15 **M. Parrino** (*New York, NY, USA*)
Developing policies to improve patient safety in medication-assisted treatment for opioid addiction
- 17:45 **A. Kastelic** (*Ljubljana, Slovenia, EU*)
Continuity of treatment from community to custodial setting and vice versa
MAIN LECTURES - Chairmen: A. Ivancic (*Porec, Croatia*) - **N. Jelovac** (*Split, Croatia*)
- 18:15 **R. Newman** (*New York, NY, USA*)
The persistent rejection of Maintenance Treatment of addiction - Why?
- 19:00 **M. Krausz** (*Vancouver, BC, Canada*)
Innovative treatment concepts for IDU with complex concurrent disorders
- 19:45 **BREAK**
- 20:30 **WELCOME COCKTAIL AND EUROPAD CHIMERA AWARD 2010**
TO BE AWARDED: Sergey Dvoryak (*Kiev, Ukraine*); **Luis Patricio** (*Lisbon, Portugal, EU*); **Slavko Sakoman** (*Zagreb, Croatia*)
CAREER AWARD: Loretta Finnegan (*Avalon, NJ, USA*) - Career Award
FORMER RECIPIENTS: Auriacombe Marc (*France*); **Blix Olof** (*Sweden*); **Deglon Jean-Jacques** (*Switzerland*); **Fischer Gabriele** (*Austria*); **Gerra Gilberto** (*Italy*); **Ivancic Ante** (*Croatia*); **Kantchelov Alexander** (*Bulgaria*); **Kastelic Andrej** (*Slovenia*); **Lovrecic Mercedes** (*Slovenia*); **Okruhlica Lubomir** (*Slovak Republic*); **Pani Pier Paolo** (*Italy*); **Torrens Marta** (*Spain*); **Touzeau Didier** (*France*)
FORMER CAREER AWARD RECIPIENTS: Lowinson Joyce (*USA*); **Maremmani Icro** (*Italy*); **Reisinger Marc** (*Belgium*); **Tagliamonte Alessandro** (*Italy*)

Saturday, May 29th, 2010

8:00 **SEANET MEETING**

MAIN LECTURES - Chairmen: *P.P. Pani (Cagliari, Italy, EU) - S. Sakoman (Zagreb, Croatia)*

9:00 **G. Gerra (UNODC, Vienna)**

Pathogenesis of substance use disorders: harm and disadvantages before psychotropics

9:30 **L. Finnegan (Avalon, NJ, USA)**

Perinatal addiction: challenges and approaches

10:30 **BREAK**

Plenary Room

Room A

I.

HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS

*Chairman: I. Maremmani
(Pisa, Italy, EU)*

11:00 **H. Waal (Oslo, Norway)**

"Europe helps Norway" - Help or problem?

11:30 **M. Reisinger (Brussels, Belgium, EU)**

Right of interference in the treatment of opiate addicts: a case study in Norway

12:00 **M. Haraldsen (Sandefjord, Norway)**

Drug related deaths in Europe – An eye-opening historical review

12:30 **I. Demaret (Liège, Belgium, EU)**

Prerequisites for the implementation of a new heroin-assisted centre

II.

GENDER DIFFERENCES IN HEROIN ADDICTS

*Chairman: L. Ignjatova
(Skopje, Republic of Macedonia)*

11:00 **L. Ignjatova (Skopje, Republic of Macedonia)**

Gender differences in patients admitted into methadone maintenance program

11:30 **M. Lovrecic (Ljubjana, Slovenia, EU)**

Is heroin addiction related to the nationality or gender?

12:00 **A.G.I. Maremmani (Pisa, Italy, EU)**

Differential substance abuse patterns distribute according to gender in heroin addicts

12:30 **M. Stenbacka (Stockholm, Sweden, EU)**

Long-term follow-ups of mortality and criminality according to gender in opiate addicts

13:00 **BREAK**

Room B

Plenary Room

III.

OPIOID ADDICTION AND PREGNANCY: THE MOTHER STUDY

*Chairman: K. Kaltenbach
(Philadelphia, PA, USA)*

11:00 **G. Fischer (Vienna, Austria, EU)**

Characteristics of US and European opioid dependent pregnant women investigated in the MOTHER study

11:30 **H. Jones (Baltimore, MD, USA)**

Neonatal and maternal results from the MOTHER study: Multi-site randomized double-blind comparison of methadone and buprenorphine.

12:00 **S. Heil (Burlington, VT, USA)**

Predictors of maternal treatment outcome in methadone and buprenorphine maintained pregnant women

12:30 **K. Kaltenbach (Philadelphia, PA, USA)**

The MOTHER study: implications for clinical practice

13:00 **BREAK**

IV.

NATIONAL REGULATIONS AND GUIDELINES FOR THE TREATMENT OF OPIOID DEPENDENCE. NECESSITIES OR OBSTACLES

*Chairman: H. Waal
(Oslo, Norway)*

15:00 **H. Waal (Oslo, Norway)**

H. Alho (Helsinki, Finland, EU)

O. Blix (Oslo, Sweden, EU)

C. Hvidt (Copenhagen, Denmark, EU)

Regulations and guidelines in the nordic countries

15:30 **R. Lubran (Rockville, MD, USA)**

US – from detailed regulations towards health oriented guidelines.

16:00 **A. Uchtenhagen (Zürich, Switzerland)**

How regulations and guidelines can develop from a national crisis

16:30 **M. M. Torrens (Barcelona, Spain, EU)**

Regulations and guidelines in a harm reduction oriented country

Room A

**V.
HEROIN ADDICTION AND INFECTIOUS DISEASES**

*Chairman: L. Somaini
(Biella, Italy, EU)*

- 15:00 **L. Somaini** (*Biella, Italy, EU*)
The role of long-acting opioids in the treatment of HCV infection in heroin dependent patients
- 15:30 **P. Chossegros** (*Lyon, France, EU*)
Can we control viral infections among drug users?
- 16:00 **F. Starace** (*Naple, Italy, EU*)
Triple diagnosis: complex treatment for complex patients
- 16:30 **S. Walcher** (*Munich, Germany, EU*)
Treatment of hep C in ORT-settings

17:00 **BREAK**

Room B

**VI.
BUPRENORPHINE: PRACTICE AND PERSPECTIVE**

*Chairman: D. Touzeau
(Paris, France, EU)*

- 15:00 **D. Touzeau** (*Paris, France, EU*)
Switch from Subutex® to Suboxone® in stable patients: results of a multicenter study
- 15:30 **P. Courty** (*Clermont Ferrand, France, EU*)
The drug is not enough: good prescription practices
- 16:00 **L. Patricio** (*Lisbon, Portugal, EU*)
Buprenorphine + naloxone: the Portuguese experience
- 16:30 **B. Nordstrand** (*Trondheim, Norway*)
Suboxone: first line drug in new Norwegian guidelines for OMT

17:00 **BREAK**

Plenary Room

**VII.
PSYCHIATRIC COMORBIDITY OF HEROIN ADDICTS**

*Chairman: P. P. Pani
(Cagliari, Italy, EU)*

- 17:30 **P.P. Pani** (*Cagliari, Italy, EU*)
The psychopathology of addiction: an open question
- 18:00 **M. M. Torrens** (*Barcelona, Spain, EU*)
Depression and illicit substance use disorders
- 18:30 **Josè Martinez-Raga** (*Valencia, Spain, EU*)
Comorbid attention deficit hyperactivity disorder (ADHD) and heroin addiction
- 19:00 **I. Maremmani** (*Pisa, Italy, EU*)
Dual diagnosis and chronology of illness in 1090 Italian heroin dependent patients

Room A

**VIII.
PSYCHOTHERAPIES FOR PATIENTS TREATED WITH OPIOID AGONISTS**

*Chairman: A. Kantchelov
(Sofia, Bulgaria, EU)*

- 17:30 **R. Bes** (*Hilversum, The Netherlands, EU*)
Motivation and medication, a therapeutic synergy
- 18:00 **A. Belchev** (*Sofia, Bulgaria, EU*)
Overcoming resistance through a cognitive perspective
- 18:30 **J. G. Love** (*Aberdeen, Scotland, UK, EU*)
Engagement and effective working with substance misusing parents: lessons from a pilot project
- 19:00 **V. Majkic** (*Belgrade, Serbia*)
Integrative model in the treatment of opioid addiction

Room B

**IX.
OFFICE-BASED TREATMENT FOR OPIATE DEPENDENCE**

*Chairman: A. Ivancic
(Porec, Croatia)*

- 17:30 **C. Ford** (*London, UK, EU*)
The quiet revolution: primary care in the UK taking on the care of people who use drugs
- 18:00 **A. Ulmer** (*Stuttgart, Germany, EU*)
Addiction treatment in general practice in Germany
- 18:30 **A. Michelazzi** (*Trieste, Italy, EU*)
The case of Sara
- 19:00 **A. Ivancic, V. Cerovecki-Nekic** (*Porec and Zagreb, Croatia, EU*)
GP's office as drug addiction clinic- Croatian experience

19:30 **BREAK**

Sunday, May 30th, 2010

- 8:00 **WFTOD MEETING** (*Word Federation for the Treatment of Opioid Dependence*)
Chairmen: A. Kastelic (Ljubljana, Slovenia, EU), I. Maremmani (Pisa, Italy, EU), M. Parrino (New York, NY, USA), M. Reisinger (Brussels, Belgium, EU)
- 9:30 **MAIN LECTURE - Chairmen: M. Reisinger (Brussels, Belgium, EU) - Z. Kljucovic (Split, Croatia)**
A. Dunlop (*Newcastle, Australia*)
Buprenorphine-Naloxone waiting list randomised controlled trial
- 10:30 **BREAK**

Plenary Room

X. OPIOID TREATMENT & ALCOHOL CONSUMPTION: MYTHS AND REALITY

*Chairman: L. Patricio
(Lisbon, Portugal)*

- 11:00 **L. Patricio** (*Lisbon, Portugal, EU*)
To deal with patients that use opioid medication and alcoholic beverages
- 11:30 **F. Pascual** (*Alicante, Spain, EU*)
Alcohol and opiates dependence. Two faces at the same problem?
- 12:00 **D. Touzeau** (*Paris, France, EU*)
Opioid maintenance treatment: role of alcohol, tobacco and cannabis
- 12:30 **A. Consoli** (*Torino, Italy, EU*)
Mental representation of alcohol consumption of Italian patients in opioid treatment program

Room A

XI. MISUSE AND RISKS IN OPIOID TREATMENT

*Chairman: R. Lubran
(Rockville, MD, USA)*

- 11:00 **R. Lubran** (*Rockville, MD, USA*)
Methadone and buprenorphine: differential risks in drug-drug interactions?
- 11:30 **R. Lubran** (*Rockville, MD, USA*)
Patient safety risk management. Overdose prevention strategies for patients on methadone or buprenorphine.
- 12:00 **J. Mørland** (*Oslo, Norway*)
Methadone and buprenorphine: drug effects and impaired driving
- 12:30 **L. Gjersing, H. Waal** (*Oslo, Norway*)
Benzodiazepine use in OMT – Patterns in outcome when OMT patients use benzodiazepines. Evidence from knowledge review and from a national follow-up study.

Room B

XII. AGONIST OPIOID TREATMENT IN EASTERN EUROPE AND FORMER SOVIET UNION

*Chairman: V. Mendelevich
(Kazan, Russia)*

- 11:00 **V. Mendelevich** (*Kazan, Russia*)
Bioethical preferences of supporters and opponents of agonist opioid treatment therapy in Russia
- 11:30 **S. Dvoryak** (*Kiev, Ukraine*)
Barriers for AOT in Ukraine and central Asia. How to overcome
- 12:00 **A. Boltaev** (*Bukhara, Uzbekistan*)
Opioid substitution therapy in Central Asia: achievements, problems and perspectives
- 12:30 **A. Alexandrov** (*Minsk, Belarus*), **O. Aizberg** (*Minsk, Belarus*)
Pilot project of MST at the Belarus: expectations and results

13:00-13:15 **CLOSING REMARKS - M. Reisinger** (*Brussels, Belgium, EU*)

13:15-13:30 **WELCOME TO THE NEXT EUROPEAN EUROPAD CONFERENCE**

FACULTY

Zuzana Alexandercikova	<i>Centre for Treatment of Drug Dependencies, Bratislava, EU</i>	<i>alexandercikova@gmail.com</i>
Alexej Alexandrov	<i>Ministry of Health, Minsk, Belarus</i>	<i>a.a.alexandrov@mail.ru</i>
Oleg Aizberg	<i>Department of Psychiatry and Addiction Medicine, Belarussian State Academy of Postgraduate Education, Minsk, Belarus</i>	<i>oleg.aizberg@gmail.com</i>
Hannu Alho	<i>University of Helsinki, Finland</i>	<i>hannu.alho@thl.fi</i>
Alexander Belchev	<i>Kantvhelov Clinic, Sofia, Bulgaria, EU</i>	<i>albelchev@hotmail.com</i>
Rik Bes	<i>Centre for Motivation and Change, MiCampus BV, Hilversum, The Netherlands, EU</i>	<i>CentreMC@hetnet.nl</i>
Olof Blix	<i>Addiction Medicine Unit, Dep of Psychiatry, County Hospital Ryhov, Jonkoping, Sweden, EU</i>	<i>olof.blix@lj.se</i>
Azizbek Boltaev	<i>Bukhara State Medical Institute, Bukhara, Uzbekistan</i>	<i>a-boltaev@mail.ru</i>
Venia Cerovecki-Nekic	<i>General Practitioner, Zagreb, Croatia</i>	<i>venija.cerovecki@mef.hr</i>
Philippe Chossegros	<i>UHSI, Centre Hospitalier Lyon-Sud , Hospices Civils de Lyon, France, EU</i>	<i>p.chossegros@wanadoo.fr</i>
Augusto Consoli	<i>Department for Addiction Prevention and Treatment "C. Olievenstein", ASL TO2, Turin, Italy, EU</i>	<i>augusto.consoli@tin.it</i>
Pascal Courty	<i>SATIS, Department of Psychiatry University Hospital G. Montpied, Clermont Ferrand, France, EU</i>	<i>pascalcourty@voila.fr</i>
Isabelle Demaret	<i>University of Liège, Belgium, EU</i>	<i>isabelle.demaret@ulg.ac.be</i>
Adrian Dunlop	<i>Drug and Alcohol Clinical Services, Newcastle Community Health Centre, Newcastle, Australia</i>	<i>Dunlop@hnehealth.nsw.gov.au</i>
Sergey Dvoryak	<i>Ukrainian Institute on Public Health Policy, Kiev, Ukraine</i>	<i>dvoryak@uiphp.org.ua</i>
Loretta Finnegan	<i>Finnegan Consulting, Inc., Avalon, NJ, USA</i>	<i>finnegal337@aol.com</i>
Gabriele Fischer	<i>Medical University of Vienna, Austria, EU</i>	<i>gabriele.fischer@meduniwien.ac.at</i>
Chris Ford	<i>General Practitioner, London, UK</i>	<i>chrishelen.ford@virgin.net</i>
Gilberto Gerra	<i>Health and Human Development Section, Division for Operations, United Nations Office on Drugs and Crime (UNODC), Vienna</i>	<i>gilberto.gerra@unodc.org</i>
Linn Gjersing	<i>Institute of Psychiatry, Center for Addiction Research, University of Oslo, Norway</i>	<i>linn.gjersing@seraf.no</i>
Martin Haraldsen	<i>General Practitioner, Sandefjord, Norway</i>	<i>mar.har@c2i.net</i>
Sarah Heil	<i>University of Vermont, Burlington, VT, USA</i>	<i>sheil@uvm.edu</i>
Christian Hvidt	<i>Social Services of the Municipality of Copenhagen, Danmark, EU</i>	<i>chistian.hvidt@SOF.kk.dk</i>
Liljana Ignjatova	<i>"St. Cyril and Metodij" Psychiatric University Hospital, Skopje, Republic of Macedonia</i>	<i>lilei@sonet.com.mk</i>
Ante Ivancic	<i>General Practitioner, Porec, Croatia</i>	<i>ante.ivancic@pu.htnet.hr</i>
Nikola Jelovac	<i>Department for Mental Health, Prevention and Outpatient Addiction Treatment, University Public Health Institute, Split, Croatia</i>	<i>nikola.jelovac@st.t-com.hr</i>
Hendree Jones	<i>Johns Hopkins University School of Medicine, Baltimore, MD, USA</i>	<i>Hjones18@jhmi.edu</i>
Karol Kaltenbach	<i>Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA</i>	<i>Karol.Kaltenbach@jefferson.edu</i>

Alexander Kantchelov	<i>Kantchelov Clinic, Sofia, Bulgaria, EU</i>	<i>al.kantchelov@gmail.com</i>
Andrej Kastelic	<i>Center for Treatment of Drug Addiction, University Psychiatric Hospital, Ljubljana, Slovenia, EU</i>	<i>andrej.kastelic@psih-klinika.si</i>
Michael Krausz	<i>St.Paul's Hospital, University of British Columbia, Vancouver, BC Canada</i>	<i>mkrausz@cheos.ubc.ca</i>
John G. Love	<i>School of Applied Social Studies, Faculty of Health & Social Care, The Robert Gordon University, Aberdeen, Scotland, UK, EU</i>	<i>j.g.love@rgu.ac.uk</i>
Mercedes Lovrecic	<i>National Institute of Public Health, Republic of Slovenia, Lubiana, Slovenia, EU</i>	<i>Mercedes.Lovrecic@ivz-rs.si</i>
Robert Lubran	<i>SAMHSA, Center for Substance Abuse Treatment, Rockville, MD, USA</i>	<i>robert.lubran@samhsa.hhs.gov</i>
Vojislav Majkic	<i>Institute for Mental Health, Belgrade, Serbia</i>	<i>vojamaj@eunet.rs</i>
Angelo G.I. Maremmani	<i>Department of Psychiatry, University of Pisa, Italy, EU -</i>	<i>angelogimaremmani@gmail.com</i>
Icro Maremmani	<i>“Santa Chiara” University Hospital, Department of Psychiatry, University of Pisa, and “G. De Lisio” Institute of Behavioural Sciences, Pisa, Italy, EU</i>	<i>maremman@med.unipi.it</i>
Ira J. Marion	<i>Albert Einstein College of Medicine, Yeshiva University, New York, NY, USA</i>	<i>ira.marion@einstein.yu.edu</i>
Jose Martinez-Raga	<i>Valencia Health Agency & University CEU Cardenal Herrera, Valencia, Spain, EU</i>	<i>jmartinezraga@comv.es</i>
Vladimir Mendelevich	<i>Kazan State Medical University, Kazan, Russia</i>	<i>mendelevich_vl@mail.ru mend@tbit.ru)</i>
Andrea Michelazzi	<i>General Practitioner, Trieste, Italy, EU</i>	<i>ermannio_michelazzi@iol.it</i>
Jørg Mørland	<i>Division of Forensic Toxicology and Substance Abuse Research, National Institute of Health, Oslo, Norway</i>	<i>jorg.morland@fhi.no</i>
Robert Newman	<i>International Center for Advancement of Addiction Treatment, Baron Edmond de Rothschild Chemical Dependency Institute of Beth Israel Medical Center, New York, NY, USA</i>	<i>rnewman@icaat.org</i>
Berit Nordstrand	<i>LAR-Midt, Trondheim, Norway</i>	<i>berit.nordstrand@rus-midt.no</i>
Lubomir Okruhlica	<i>Centre for Treatment of Drug Dependencies, Bratislava, Slovak Republic, EU</i>	<i>okruhlica@cpldz.sk</i>
Matteo Pacini	<i>"G. De Lisio" Institute of Behavioural Sciences, Pisa, Italy</i>	<i>paciland@virgilio.it</i>
Pier Paolo Pani	<i>Social-Health Service, Health District 8 (ASL 8), Cagliari, Italy, EU</i>	<i>pallolo@tin.it</i>
Mark Parrino	<i>AATOD, New York, NY, USA</i>	<i>Mark.Parrino@aatod.org</i>
Francisco Pascual	<i>Hospital General de Elda, Alicante, Spain, EU</i>	<i>fr.pascualp@coma.es</i>
Luis Patricio	<i>Psychiatrist Consultant Co-founder and former Director of Centro das TAIPAS, Health Ministry, Lisbon, Portugal, EU</i>	<i>luispatricio@sapo.pt</i>
Maria Chiara Pieri	<i>SerT Bologna, Italy, EU</i>	<i>chiara.pieri@ausl.bologna.it</i>
Marc Reisinger	<i>EUROPAD, Bruxelles, Belgium, EU</i>	<i>m.reisinger@numericable.be</i>
Carlos Roncero Alonso	<i>Vall d'Hebron Hospital, Psychiatry Service, Barcelona, Spain, EU</i>	<i>croncero@vhebron.net</i>
Lorenzo Somaini	<i>SerT Biella, Italy, EU</i>	<i>Lorenzo.Somaini@aslbi.piemonte.it</i>
Fabrizio Starace	<i>Lyason Psychiatry Unit, Cotugno University Hospital, Naples, Italy, EU</i>	<i>fabrizio.starace@tin.it</i>

Marlene Stenbacka	<i>Karolinska Institute, Karolinska Hospital, Stockholm, Sweden, EU</i>	<i>marlene.stenbacka@sl.se</i>
Heino Stöver	<i>University of Applied Sciences, Faculty of Health and Social Work, Frankfurt, Germany, EU</i>	<i>hstoever@fb4.fh-frankfurt.de</i>
Martha Melich Torrens	<i>University of Barcelona, Institute of Psychiatry and Addictions, Barcelona, Spain, EU</i>	<i>MTorrens@imim.es</i>
Marija Toseva	<i>Healthy Option Project Skopje (HOPS), Skopje, Republic of Macedonia</i>	<i>marijat@hops.org.mk</i>
Didier Touzeau	<i>Clinique Liberté, Bagneux, France, EU</i>	<i>didier.touzeau@noos.fr</i>
Ambros Uchtenhagen	<i>Research Institute for Public Health and Addiction, Zürich, Switzerland</i>	<i>uchtenhagen@isgf.uzh.ch</i>
Albrecht Ulmer	<i>General Practitioner, Stuttgart, Germany, EU</i>	<i>albrecht.ulmer@gmx.de</i>
Peter Vossenber	<i>Tactus (Addiction Treatment), Deventer, Netherlands, EU</i>	<i>p.vossenber@tactus.nl</i>
Helge Waal	<i>University of Oslo, Institute of Psychiatry, Center for Addiction Research, Oslo, Norway</i>	<i>helge.waal@medisin.uio.no</i>
Stephan Walcher	<i>Centre for Addiction Treatment - CONCEPT - Munich, Germany, EU</i>	<i>kontakt@moviemed.de</i>

POSTER SESSION

- P1 **Influence of Socio-Demographic Issues in Body Mass Index (Bmi) and Dietary Habits of Heroin Addicts in Methadone Maintenance Treatment**
D. Alves, A. Costa, D. Custódio, L. Natário and V. Ferro-Lebres
Polytechnic Institute of Bragança, Portugal, EU - addl_diet@hotmail.com
- P2 **Treatment's Monitoring by Agonist Opioid in Heroin Addicts in Naples Italy**
C. Baldassarre, F. Curcio, M. Siconolfi and L. Vrenna
ASL Napoli 1 Centro, Italy, EU - c_baldassarre@virgilio.it
- P3 **Initiation to Heroin Use in a Polysubstance Context: Characteristics of First-Ever Heroin Experiences in a Treatment-Seeking Canadian Sample**
S. P. Barrett
Dalhousie University, Canada - sean.barrett@dal.ca
- P4 **The existence of a plasma acute phase protein (alpha 1-acid glycoprotein) may contribute to the limited success of methadone therapy in vivo**
J. Behan¹, M. Bruce², Y. Cruikshank¹ and K. Smith¹
¹ Department of Life Sciences, Edinburgh Napier University, Merchiston, Scotland, UK, EU
² Community Drug Problem Service, Edinburgh, Scotland, UK, EU - J.Behan@napier.ac.uk
- P5 **The epidemiology of opiate disorders in the psychiatric emergency room, 2003-2008**
R. Bruffaerts¹, M. Sabbe², D. Koen¹
¹ Department of Neuroscience, Katholieke Universiteit Leuven, Belgium, EU
² Department of Emergency Medicine, Katholieke Universiteit Leuven, Belgium, EU- ronny.bruffaerts@med.kuleuven.be
- P6 **Tttc Study (TogetherTo Take Care): Management of Teraphy for Hepatitis C Addicted**
F. Curcio, C. Baldassarre and P. Filippini
ASL Napoli 1 Centro - Italy - c_baldassarre@virgilio.it
- P7 **Cytochrome P450 and Abcb1 Genetic Polymorphisms and Methadone Plasmatic Concentrations in Opioid Dependence Disorder**
F. Fonseca, A. Pastor, E. Cuyas, K. Langohr, R. Martin-Santos, M. Farrè, R. de la Torre and M. Torrens
Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar de Barcelona - 94158@parcdesalutmar.cat
- P8 **Activities Primary and Secondary Prevention of Hcv Infection and Hiv in Cantonal Institute for the Fight against Disease Addiction Zenica First Year Experience**
S. Kasper
Cantonal Institut for addiction Zenica, Bosnia & Erzegovina - samirkasper@hotmail.com
- P9 **Stationary Treatment with Dual Psychiatric Diagnosis in the Cantonal Institut for Addiction Zenica 2008-2010 Year**
S. Kasper, J. Softic, A. Cerim and H. Awad
Cantonal Institut for addiction Zenica, Bosnia & Erzegovina - samirkasper@hotmail.com
- P10 **Psychotherapy Spouses and Parents Addicted to Opiates in Cantonal Institute for the Fight against Disease Addiction Zenica**
S. Kasper, J. Softic, A. Cerim and H. Awad
Cantonal Institut for addiction Zenica, Bosnia & Erzegovina - samirkasper@hotmail.com
- P11 **Recruitment of Young Drug Addicts to a Drug-Free Therapeutic Program through Short-Term Buprenorphine Use**
E. Koutsopoulou
Greek Organisation Against Drugs (OKANA), Greece - koutsopoulou@yahoo.com

- P12 Cardiovascular Effect of Concomitant Use Opioid and Cocaine among Young People: A Record Linkage Study**
V. Lorenzoni, A. Cutilli, A. Barnabei and S. Molinaro
Institute of Clinical Physiology, National Research Council (CNR), Pisa, Italy - lorenzoni@ifc.cnr.it
- P13 Ethnic and gender specific differences in the prevalence of HIV among patients in opioid substitution treatment – a case register analysis**
M. Liebreuz, R. Stohler, C. Nordt
Research Group on Substance Use Disorders, Psychiatric University Hospital, Zurich, Switzerland. - Michael.Liebreuz@puk.zh.ch
- P14 Ascertainment of Individual Specifications of Addicts Admitted to Tehran Treatment Centers**
M. Moraveji and M. Bazargan
Zanjan Azad University, Tehran - mahtabmoraveji@yahoo.com
- P15 Psychotherapeutic Accessibility of Opiate Dependent Patients**
R. Podkrajek
CPZOPD Logatec, Slovenia- rok.podkrajsek@gmail.com
- P16 Substitution Drugs and Drive**
J. C. Rupnik
CPZOPD Logatec Slovenia - cpzopd@zd-logatec.si
- P17 Heroin Use and Eating Disorders among Italian Students: What About Gender Differences?**
V. Siciliano, O. Curzio, F. Denoth and S. Molinaro
Clinical Physiology Institute, National Council Research, Pisa, Italy - valeria.siciliano@ifc.cnr.it
- P18 The Constant of Pleasure**
J. Softic
Cantonal institution for the fighting the addiction Zenica, Bosnia and Hercegovina - jsoftic@yahoo.com
- P19 Comparing Methadone and Suboxone in Applied Treatment Settings: The Experiences of Maintenance Patients in Lanarkshire**
G. Tanner
NHS Lanarkshire, Scotland, GB - garytanner@nhs.net
- P20 A Comparison between Needle Users and Non-Users from a Cultural, Social, Environmental and Mental Health Perspective**
S. Thurairajasingam
Monash University Malaysia - sivakumar.thurairajasingam@med.monash.edu.my
- P21 Effectiveness of Sertraline in Methadone Maintenance Treatment with Poor Efficacy**
A. S. Trajanovska and V. Vujovic
Day Hospital for drug addiction, Psychiatric Hospital, Skopje, Republic of Macedonia - anetaspas@gmail.com

Thanks to



for the welcome contributions to the Conference costs